RTOG-1106

Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator

Feng-Ming (Spring) Kong

Status

Disease Site

Lung [LU] Non-small Cell Lung Cancer

Phase

II

Developmental Therapeutics

No

Primary Objective

RTOG: To determine whether tumor dose can be escalated to improve the LRPF rate at 2 years when an individualized adaptive radiation treatment (RT) plan is applied by the use of a FDG-PET/CT scan acquired at 40-46 Gy initial dose of RT in patients with inoperable or unresectable stage III NSCLC

ACRIN: To determine whether the relative change in SUV/peak from the baseline to the during-treatment FDG-PET/CT, defined as (during-treatment SUVpeak – baseline SUVpeak) baseline SUVpeak X 100%, can predict the LRPF with a 2-year follow up.

See “ACRIN Information” in the left column of this page.

RT Credentialing: Please see section 5 for specific details

Lung Atlas

Data Collection Notice:

Data for this trial is being collected via the NRG/RTOG Data Center.

Patient Population

Patients with FDG-avid and histologically or cytologically proven AJCC stage IIIA or IIIB, non-operable NSCLC

Target Accrual

138